476.8

+0.21%↑

SANES

10.354

-1.99%↓

SAF

280.3

+2.94%↑

BBVA

18.715

-1.58%↓

BNP

90.44

-0.47%↓

476.8

+0.21%↑

SANES

10.354

-1.99%↓

SAF

280.3

+2.94%↑

BBVA

18.715

-1.58%↓

BNP

90.44

-0.47%↓

476.8

+0.21%↑

SANES

10.354

-1.99%↓

SAF

280.3

+2.94%↑

BBVA

18.715

-1.58%↓

BNP

90.44

-0.47%↓

476.8

+0.21%↑

SANES

10.354

-1.99%↓

SAF

280.3

+2.94%↑

BBVA

18.715

-1.58%↓

BNP

90.44

-0.47%↓

476.8

+0.21%↑

SANES

10.354

-1.99%↓

SAF

280.3

+2.94%↑

BBVA

18.715

-1.58%↓

BNP

90.44

-0.47%↓

Home・Akcijų sąrašas・AB Science SA

AB Science SA

Uždarymo kaina

1.138 -0.18

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.134

Max

1.17

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-5.2M
Pardavimai	515K
Pelno marža	-1,005.243
Darbuotojai	36
EBITDA	-2.5M

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-11

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	77M
Ankstesnė atidarymo kaina	1.32
Ankstesnė uždarymo kaina	1.138

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

1.426 / 1.448 Palaikymas ir pasipriešinimas

AB Science SA Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-24 00:00; UTC

Uždarbis

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

2026-04-24 00:00; UTC

Uždarbis

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

2026-04-23 23:47; UTC

Rinkos pokalbiai

Gold Edges Lower Amid Ongoing Concerns Over Higher Inflation -- Market Talk

2026-04-23 23:43; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-23 23:43; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-23 23:43; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Uncertainty Over U.S.-Iran Conflict -- Market Talk

2026-04-23 23:13; UTC

Įsigijimai, susijungimai, perėmimai

Trump on Spirit Airlines: 'I Think We'd Just Buy It' -- Update

2026-04-23 22:33; UTC

Uždarbis

Intel Shares Jump 20% as AI Agents Drive Big Growth -- WSJ

2026-04-23 22:17; UTC

Uždarbis

PLS Executed Offtake Agreement With Ronbay

2026-04-23 22:17; UTC

Uždarbis

PLS Secured Up to A$38.1M in Australia Government ARENA Grant Funding

2026-04-23 22:16; UTC

Uždarbis

PLS Commences Commissioning of Midstream Demonstration Plant

2026-04-23 22:15; UTC

Uždarbis

PLS Group Reaffirms FY26 Guidance for All Metrics

2026-04-23 22:14; UTC

Uždarbis

PLS Group 3Q Cash Margin From Operations A$461M at March 31

2026-04-23 22:14; UTC

Uždarbis

PLS Group 3Q Cash Balance A$1.455 Billion at March 31

2026-04-23 22:13; UTC

Uždarbis

PLS Group 3Q Unit Operating Cost A$733/Ton CIF, Up 2% on 2Q

2026-04-23 22:12; UTC

Uždarbis

Correct: PLS Group 3Q Unit Operating Cost A$520/Ton FOB, Down 11% on 2Q

2026-04-23 22:12; UTC

Uždarbis

PLS Group 3Q Unit Operating Cost US$520/Ton FOB, Down 11% on 2Q

2026-04-23 22:11; UTC

Uždarbis

PLS Group 3Q Realized Price US$1,867/Ton, Up 61% on 2Q

2026-04-23 22:10; UTC

Uždarbis

PLS Group 3Q Revenue A$567,000, Up 52% on 2Q

2026-04-23 22:09; UTC

Uždarbis

PLS Group 3Q Sales 195,700 Tons, Down 16% on 2Q

2026-04-23 22:08; UTC

Uždarbis

PLS Group 3Q Production 232,400 Tons, Up 12% on 2Q

2026-04-23 22:04; UTC

Uždarbis

Intel Sales Rise 7% as AI Agents Drive Growth -- WSJ

2026-04-23 21:56; UTC

Rinkos pokalbiai

Uždarbis

Intel Points to Growing Role of CPUs Amid AI Shifts -- Market Talk

2026-04-23 21:48; UTC

Įsigijimai, susijungimai, perėmimai

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

2026-04-23 21:27; UTC

Uždarbis

Intel CFO: All Demand Signals Point to Growing Role of CPUs in AI Era

2026-04-23 21:25; UTC

Uždarbis

Intel CFO Expects Factories to Continue Increasing Supply in 3Q, 4Q, but at More Measured Pace Than Previously Expected

2026-04-23 21:24; UTC

Uždarbis

SAP Stock Rebounds From Software Slaughter. The Cloud Boosted Europe's Tech Titan. -- Barrons.com

2026-04-23 21:24; UTC

Uždarbis

Blackstone Stock Falls After Earnings. Private Credit Remains in Focus. -- Barrons.com

2026-04-23 21:21; UTC

Uždarbis

Intel to Look for Unconventional Way to Boost Manufacturing Capacity Through Musk's Terafab Project, CEO Says

2026-04-23 21:21; UTC

Uždarbis

Intel CEO: He, Elon Musk Believe Global Semiconductor Supply Isn't Keeping Up With Accelerating Demand

Akcijų palyginimas

Kainos pokytis

AB Science SA Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

Pirkti

Laikyti

Parduoti

Remiantis 0 analitikų, pateikusių AB Science SA akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.426 / 1.448Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę AB Science SA

AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company's lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer's disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.